Geneva, Switzerland, 26 September 2025 – 6:00 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a September 25, 2025, judgment, granted GeNeuro SA an extension of its definitive debt-restructuring moratorium until January 27, 2026, under the continued supervision of the court-appointed commissary.
Definitive Debt-Restructuring Moratorium
As previously announced, GeNeuro SA had obtained on May 26, 2025, a definitive debt-restructuring moratorium of four months, extendable, which aimed to allow GeNeuro SA to further its efforts to evaluate all available options, including recapitalization, advancing and/or monetizing its therapeutic assets in development, and negotiating agreements with its creditors. These efforts remain centered on maximizing value for all stakeholders and ensuring the Company’s ability to continue its mission to develop innovative treatments targeting neurodegenerative and autoimmune diseases.
The four-month extension of this definitive moratorium ensures that GeNeuro SA remains protected from creditor actions while it continues to develop and implement its restructuring strategy. Any significant developments will be communicated as appropriate.